Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. QXO (NYSE:QXO) Head-To-Head Analysis

QXO (NYSE:QXO) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both industrials companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Risk and Volatility

QXO has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500.

Earnings & Valuation

This table compares QXO and Cyclacel Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QXO	$9.90 billion	1.29	-$279.40 million	($0.90)	-13.64
Cyclacel Pharmaceuticals	$1.86 million	2.59	-$3.00 million	($3.64)	-0.24

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than QXO. QXO is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

58.7% of QXO shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 41.0% of QXO shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares QXO and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QXO	-5.17%	2.41%	1.20%
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Analyst Recommendations

This is a breakdown of current ratings and price targets for QXO and Cyclacel Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QXO	1	1	13	2	2.94
Cyclacel Pharmaceuticals	1	0	0	0	1.00

QXO presently has a consensus price target of $28.00, indicating a potential upside of 128.11%. Given QXO’s stronger consensus rating and higher probable upside, analysts clearly believe QXO is more favorable than Cyclacel Pharmaceuticals.

Summary

QXO beats Cyclacel Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About QXO

QXO, Inc. operates as a business application, technology, and consulting company in North America. The company provides solutions for accounting and business management, financial reporting, enterprise resource planning, human capital management, warehouse management systems, customer relationship management, and business intelligence. It also offers value-added services that focuses on consulting and professional, specialized programming, training, and technical support services. In addition, the company provides information technology managed services, such as cybersecurity, application hosting, disaster recovery, business continuity, cloud, and other services; and data back-up, network maintenance, and upgrade services. It serves small and medium-sized businesses primarily in the manufacturing, distribution, and service industries. QXO, Inc. is headquartered in Greenwich, Connecticut.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.